Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
|
|
- Corey Ellis
- 6 years ago
- Views:
Transcription
1 Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale, PharmD INTRODUCTION According to the National Institutes of Health, chemotherapy-induced nausea and vomiting (CINV) is a debilitating adverse event caused by cancer treatments that has a significant impact on a patient s quality of life if not prevented or controlled adequately. 1 CINV can be defined as acute, delayed, or anticipatory. Acute CINV occurs within 24 hours after chemotherapy. Delayed CINV begins 24 hours or more after chemotherapy and can last up to several days after the treatment is complete. Delayed nausea is more common than acute nausea, and it is more severe and harder to treat. 2 Anticipatory CINV can occur in up to 25% of patients as a result of conditioning from stimuli associated with chemotherapy, usually occurring within 12 hours prior to treatment administration. 3 The emetogenic potential of chemotherapeutic agents varies in severity (Table 1). Highly emetogenic chemotherapy (HEC) regimens have a greater than 90% incidence of CINV. Moderately emetogenic chemotherapy (MEC) and low emetogenic chemotherapy (LEC) regimens have a 30% to 90% and 10% to 30% incidence of CINV, respectively. 3 It is theorized that CINV is triggered by the release of neurotransmitters, namely serotonin and substance P, from one of Dr. Goldberg is an Associate Professor of Pharmacy Practice and Dr. Fidler is an Assistant Professor of Pharmacy Practice at the Arnold and Marie Schwartz College of Pharmacy and Health Sciences at Long Island University in Brooklyn, New York. Dr. Cardinale is a PGY-2 Ambulatory Care Resident at King Pharmacy in Brooklyn, New York. Drug Forecast is a regular column coordinated by Alan Caspi, PhD, PharmD, MBA, President of Caspi and Associates in New York, New York. Disclosures: The authors report no financial or commercial relationships in regard to this article. several pathways that activate the vomiting center in the medulla. The two pathways thought to influence CINV include one in the gastrointestinal (GI) tract and another in the chemoreceptor trigger zone. 3 Nausea is not always followed by vomiting; other clinical manifestations that may accompany nausea include tachycardia, perspiration, light-headedness, dizziness, pallor, excess salivation, anorexia, and weakness. 3 Many therapies are available to prevent and treat CINV via the oral (Table 2), intravenous, and trans dermal routes To prevent acute CINV, 5-hydroxytryptamine 3 (5-HT 3 ) serotonin receptor antagonists are often administered; neurokinin-1 (NK1) receptor antagonists are used for both acute and delayed CINV. 11 Cortico steroids, specifically methylprednisolone or dexamethasone, can be used as single agents or in combination with 5-HT 3 receptor antagonists and/or NK1 receptor antagonists. Metoclopramide, chlorpropamide, and cannabinoids are recommended only when a patient is experiencing CINV that is refractory to 5-HT 3 and/or NK1 receptor antagonists. Benzodiazepines may be beneficial in patients experiencing anticipatory nausea. 3 The most recent National Comprehensive Cancer Network (NCCN) guidelines for antiemesis recommend the administration of a 5-HT 3 antagonist in combination with an NK1 antagonist for the prevention of CINV due to HEC regimens. For the prevention of CINV due to MEC regimens, a 5-HT 3 antagonist with or without an NK1 antagonist is recommended by the same guidelines. 2 The Food and Drug Administration (FDA) approved the first substance P/ NK1 receptor antagonist, aprepitant (Emend capsules or oral suspension, Merck Sharp & Dohme Corp.), in A combination substance P/NK1 antagonist 5-HT 3 antagonist (netupitant/ palonosetron [Akynzeo, Eisai]) was approved by the FDA in Most recently, the FDA approved the 5-HT 3 antagonist rolapitant (Varubi, Tesaro) in This Drug Forecast will focus on rolapitant. INDICATION Rolapitant is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, HEC. 5 Table 1 Emetogenic Potential of Select Chemotherapeutic Agents 3 High Moderate Low Cisplatin Mechlorethamine Streptozocin Cyclophosphamide (> 1,500 mg/m 2 ) Oxaliplatin Cytarabine (> 1 g/m 2 ) Carboplatin Irinotecan Ifosfamide Doxorubicin Daunorubicin Epirubicin Idarubicin Paclitaxel Docetaxel Mitoxantrone Pemetrexed Etoposide Trastuzumab Methotrexate Mitomycin C Gemcitabine Cytarabine (< 100 mg/m 2 ) 5-Fluorouracil Bortezomib Cetuximab 168 P&T March 2017 Vol. 42 No. 3
2 Table 2 A Comparison of Select Treatments for CINV (Tablet/Capsule Formulations) Drug (Brand Name, Manufacturer) Initial Approval Indication(s) Recommended Dosage AWP per Unit 10 Substance P/NK1 Receptor Antagonists Aprepitant a (Emend capsules, Merck Sharp & Dohme Corp.) In combination with other antiemetic agents in patients 12 years of age and older for prevention of: Acute and delayed nausea and vomiting associated with initial and repeat courses of HEC, including high-dose cisplatin repeat courses of MEC Also for prevention of PONV in adults only Rolapitant (Varubi tablets, Tesaro) In combination with other antiemetic agents in adults for prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, HEC 5-HT 3 Antagonists Dolasetron mesylate b (Anzemet tablets, Sanofi-Aventis) 6 Granisetron c (generic tablets, multiple manufacturers) 7 Ondansetron d (generic tablets, multiple manufacturers) In adults and children 2 years of age and older for prevention of nausea and vomiting associated with MEC, including initial and repeat courses 1995 In adults for: repeat courses of emetogenic cancer therapy, including high-dose cisplatin Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation 1992 In patients 4 years of age and older for: Nausea and vomiting associated with HEC, including cisplatin greater than or equal to 50 mg/m 2 repeat courses of MEC Nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen PONV Combination Substance P/NK1 Receptor Antagonist With 5-HT 3 Antagonist Netupitant/palonosetron (Akynzeo capsules, Eisai, Inc.) In adults for acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, HEC 125 mg administered within one hour before chemotherapy on day 1 80 mg on days 2 and mg administered approximately one to two hours prior to chemotherapy on day 1 Adults = 100 mg Patients 2 16 years of age = 1.8 mg/kg (maximum 100 mg) Administer within one hour before chemotherapy See prescribing information of concomitant drugs for dosage and administration instructions See ondansetron prescribing information for dosage and administration instructions One 300-mg netupitant/ 0.5-mg palonosetron capsule administered approximately one hour prior to the start of chemotherapy $129 per 40-mg capsule $239 per 80-mg capsule $373 per 125-mg capsule $337 per 90-mg tablet $86 per 50-mg tablet $115 per 100-mg tablet $7 per 1-mg tablet $25 per 4-mg tablet $41 per 8-mg tablet $659 per capsule a Also available in oral suspension and IV formulations b Also available in IV formulation c Also available in IV, ER transdermal film, and ER subcutaneous injection formulations d Also available in oral solution, orally disintegrating tablet, oral soluble film, and IV formulations 5-HT 3 = 5-hydroxytryptamine 3; AWP = average wholesale price; CINV = chemotherapy-induced nausea and vomiting; ER = extended-release; HEC = highly emetogenic chemotherapy; IV = intravenous; MEC = moderately emetogenic chemotherapy; NK1 = neurokinin-1; PONV = postoperative nausea and vomiting Vol. 42 No. 3 March 2017 P&T 169
3 MECHANISM OF ACTION Rolapitant is a selective and competitive antagonist of human substance P/ NK1 receptors with antiemetic activity. 5 Rolapitant crosses the blood brain barrier and occupies NK1 receptors in the brain. Substance P and NK1 receptors are present in the brain stem (medulla) centers that control the emetic reflex. Substance P is a peptide that increases the contractions of smooth GI muscles and leads to vasodilation. NK1 receptors are present on motor neurons in the stomach that are responsible for the physiological and pathological behaviors of the stomach, such as gastric relaxation, emesis, or stasis. 12 Rolapitant does not have significant affinity for the NK2 or NK3 receptors or for a battery of other receptors, transporters, enzymes, and ion channels. 12 PHARMACOKINETICS Rolapitant, which is eliminated primarily through the liver, is metabolized by cytochrome P450 (CYP) 3A4 to form the major circulating active metabolite C4-pyrrolidine-hydroxylated rolapitant (M19). 13 Excretion studies have shown that six weeks after a single dose of rolapitant, 14.2% and 73% of the dose was found in the urine and feces, respectively. Administration of rolapitant with a high-fat meal did not significantly affect absorption. Elimination studies revealed the halflife of rolapitant to be approximately seven days. Age, gender, or race do not have an effect on the pharmacokinetic profile of rolapitant. 5 DOSAGE AND ADMINISTRATION The recommended dosage of rolapitant is 180 mg (two 90-mg tablets) administered orally as a single dose one to two hours prior to the start of chemotherapy on day 1 with or without food. Rolapitant is indicated for use in combination with a corticosteroid (i.e., dexamethasone) and a 5-HT 3 antagonist. Granisetron was the 5-HT 3 antagonist utilized in all of the clinical trials of rolapitant. Rolapitant should not be given more than once every 14 days. 5 No dosage adjustment is necessary for patients with mild or moderate renal or hepatic impairment; however, patients with severe renal or hepatic impairment should avoid rolapitant or be closely monitored for adverse reactions. 5 DRUG INTERACTIONS Based upon pharmacokinetic studies, rolapitant is a CYP3A4 substrate and a moderate inhibitor of CYP2D6, breast cancer resistance protein (BCRP) transporter, and P-glycoprotein (P-gp) transporter. 14 Use of rolapitant should be avoided in patients taking pimozide (Orap, Teva) or thioridazine due to potential QT prolongation, which may result in torsades de pointes, a potentially fatal complication. 5 The CYP2D6 inhibition of rolapitant lasts at least seven days; however, it is possible that this activity lasts beyond that time frame. If CYP2D6 inhibitors cannot be avoided, patients need to be monitored for QT prolongation and adverse re actions caused by the substrate drug. The lowest effective dose of BCRP substrates (i.e., methotrexate, topotecan, rosuvastatin) and P-gp substrates (i.e., digoxin) are recommended when coadministered with rolapitant. 5 Strong CYP3A4 inducers (i.e., rifampin) may significantly reduce the plasma concentration of rolapitant and, therefore, coadministration of rolapitant with such agents should be avoided. 5 ADVERSE EVENTS Although rolapitant is well tolerated, constipation, headache, fatigue, dizziness, dyspepsia, hiccups, and neutropenia have been observed in treated patients. However, the percentage of patients reporting adverse effects in phase 3 trials did not differ significantly in the study groups compared with the control groups. 5,15,16 One phase 3 trial reported that only 4% of patients receiving HEC discontinued rolapitant due to side effects compared with 5% in the control group. 16 Patients receiving MEC had the same discontinuation rate when comparing the rolapitant group (2%) with the control group (2%). 15 The severity of neutropenia was evaluated in all phase 3 trials using a grading scale ranging from mild (grade 1) to fatal (grade 5). In patients receiving MEC or HEC and rolapitant, no grade 5 neutropenia was reported, and the percentage of patients reporting grade 3 and grade 4 neutropenia did not differ significantly between the study and control groups. 15,16 A recent retrospective meta-analysis reviewed antiemetic regimens with aprepitant, rolapitant, and netupitant/ palonosetron plus a steroid and a 5-HT 3 antagonist. 16 Compared with the aprepitant regimen, rolapitant had the lowest incidence of constipation (23.9% for aprepitant versus 0.4% for rolapitant) and hiccups (35.5% versus 0.6%, respectively). 16 There were insufficient data on the incidence of adverse effects for netupitant/ palonosetron and rolapitant to make a comparative analysis. CLINICAL TRIALS Rolapitant s FDA approval was based on three pivotal phase 3 clinical trials (Table 3). The primary endpoint in all three studies was complete response to therapy, defined as no emetic episodes and no need for rescue medication in the delayed phase after the initiation of chemotherapy (more than 24 hours to 120 hours). The primary endpoint results were similar in all three studies and demonstrated the statistically significant superiority of the rolapitant regimen over control therapy. Each study also had two key secondary endpoints in common: 1) the proportion of patients with complete responses in the acute phase after chemotherapy (0 to 24 hours) and 2) overall response after chemotherapy (0 to 120 hours). 15,16 HEC 1 and HEC 2 Trials In two global, multicenter, randomized, double-blind, active-controlled clinical studies (HEC 1 and HEC 2), a rolapitant regimen (180 mg rolapitant plus granisetron and dexamethasone) was compared with control therapy (placebo plus granisetron and dexamethasone) in patients receiving a cisplatin-based chemotherapy regimen. All regimens were administered one to two hours prior to chemotherapy. 16 The HEC 1 study enrolled a total of 532 patients who were randomized to receive a rolapitant-containing regimen (n = 266) or control therapy (n = 266) for up to five cycles of chemo therapy. The intention to treat (ITT) efficacy evaluation included 526 patients. In this study, 82% of the patients received a concomitant chemotherapeutic agent in addition to the protocol-mandated cisplatin. Common concomitant chemotherapeutic agents included gemcitabine (17%), paclitaxel (12%), fluorouracil (11%), 170 P&T March 2017 Vol. 42 No. 3
4 Table 3 Rolapitant Phase 3 Clinical Trials: Complete Response to Therapy, Defined as No Emetic Episodes and No Need for Rescue Medication in the Delayed Phase After Initiation of Chemotherapy (> 24 to 120 Hours) Trial Description Dosing Results Conclusion HEC 1 Rapoport et al. (2015) 16 HEC 2 Rapoport et al. (2015) 16 MEC Schwartzberg et al. (2015) 15 Global, multicenter, randomized, double-blind, active-controlled study with 526 patients receiving a rolapitant-containing regimen (n = 264) or control therapy (n = 262) for up to five cycles of chemotherapy Global, multicenter, randomized, double-blind, active-controlled study with 544 patients receiving a rolapitant-containing regimen (n = 271) or control therapy (n = 273) for up to five cycles of chemotherapy Multicenter, randomized, double-blind, parallel-group, active-controlled clinical study with 1,369 patients randomized to a rolapitantcontaining regimen (n = 684) or control therapy (n = 685) for up to five cycles of chemotherapy One 180-mg dose of oral rolapitant or placebo identical in appearance one to two hours before administration of chemotherapy All patients received granisetron (10 mcg/kg IV) and dexamethasone (20 mg orally) on day 1, and dexamethasone (8 mg orally) twice daily on days 2 4 One 180-mg dose of oral rolapitant or placebo identical in appearance one to two hours before administration of chemotherapy All patients received granisetron (2 mg orally) and dexamethasone (20 mg orally) on day 1 (except for patients receiving taxanes who received dexamethasone according to the package insert) and granisetron (2 mg orally) on days % of patients in the primary endpoint versus 58% for the control therapy group (OR, 1.9; 95% CI, ; P = ) 70% of patients in the primary endpoint versus 62% for the control therapy group (OR, 1.4; 95% CI, ; P = ) 71% of patients in the primary endpoint versus 62% in the control therapy group (OR, 1.6; 95% CI, ; P = ) Addition of rolapitant significantly improved control of CINV Addition of rolapitant significantly improved control of CINV CI = confidence interval; CINV = chemotherapy-induced nausea and vomiting; HEC = highly emetogenic chemotherapy; IV = intravenously; MEC = moderately emetogenic chemotherapy; OR = odds ratio and etoposide (10%). The mean cisplatin dose was 77 mg/m The HEC 2 trial enrolled a total of 555 patients who were randomized to either a rolapitant-containing regimen (n = 278) or control therapy (n = 277). A total of 544 patients were included in the ITT efficacy analysis. During this study, 85% of patients received a concomitant chemotherapeutic agent in addition to protocol-mandated cisplatin, including vinorelbine (16%), gemcitabine (15%), fluorouracil (12%), and etoposide (11%). The mean cisplatin dose was 76 mg/m In the pooled analysis for the HEC 1 and 2 studies, 71% of patients in the rolapitant regimen achieved the primary endpoint versus 60% for the control therapy group (odds ratio [OR], 1.6; 95% confidence interval [CI], ; P = ). In addition, in the pooled data analysis, the rolapitant regimen demonstrated superiority in both of the secondary endpoints versus control therapy (acute phase: OR, 1.6; 95% CI, ; P = ; overall: OR, 1.6; 95% CI ; P = ). 16 MEC Trial This multicenter, randomized, doubleblind, parallel-group, active-controlled clinical study in MEC evaluated a rolapitant regimen (rolapitant plus granisetron and dexamethasone) compared with control therapy (placebo plus granisetron and dexamethasone) in patients receiving an MEC regimen that included at least 50% of patients receiving a combination of anthracycline and cyclophosphamide. A total of 1,369 patients were randomized to either the rolapitant regimen (n = 684) or control therapy (n = 685). A total of 1,332 patients were included in the ITT efficacy evaluation. 15 In the MEC study, the rolapitant regimen outperformed control therapy, with 71% of patients achieving the primary endpoint versus 62% in the control therapy arm (OR 1.6; 95% CI, 1.2 2; P = ). The proportion of patients achieving the secondary endpoints was higher in the rolapitant therapy arm compared with the control therapy arm; however, the rolapitant therapy arm demonstrated a statistically significant difference only in overall response versus the control arm (acute phase: OR, 1.2; 95% CI, ; P = ; overall: OR, 1.6; 95% CI ; P = ). 15 COST 10 The average wholesale prices (AWPs) per unit for rolapitant and other oral antiemetics for CINV are listed in Table 2. Rolapitant is manufactured as a 90-mg tablet with an AWP of $337 per tablet, Vol. 42 No. 3 March 2017 P&T 171
5 and it is supplied in a two-tablet blister pack. Therefore, the recommended 180-mg dose administered to the patient on day 1 of chemotherapy results in an AWP of $674 for a single treatment. Rolapitant must be administered in conjunction with dexamethasone and a 5-HT 3 antagonist, which will add minimal additional cost. Rolapitant may be administered at the start of each chemotherapy cycle. There are two comparator agents for CINV within the same therapeutic class as rolapitant: aprepitant and netupitant/ palonosetron. Each treatment may be utilized for repeat courses of chemotherapy. Aprepitant is recommended on day 1 of chemotherapy at a dosage of 125 mg (AWP $373 per capsule), and then at a dosage of 80 mg (AWP $239 per capsule) on days 2 and 3 for a total AWP of $851 per chemotherapy cycle. Like rolapitant, it is administered along with dexamethasone and a 5-HT 3 antagonist. Netupitant/ palonosetron is administered as a single dose on day 1 of chemotherapy and is priced comparatively with rolapitant at an AWP of $659 per capsule. It is also given along with dexamethasone. P&T COMMITTEE CONSIDERATIONS The discovery of substance P/NK1 receptor antagonists has led to a significant patient care breakthrough that decreases CINV incidence to less than 16% when used in combination with 5-HT 3 antagonists and dexamethasone. 17 Based on the NCCN Clinical Practice Guidelines in Oncology, 2 rolapitant could be considered for acute-phase treatment for MEC in a combination regimen with a 5-HT 3 antagonist and dexamethasone. 18 Historically, 5-HT 3 receptor antagonists were able to prevent emesis in approximately 50% of patients. The addition of dexamethasone to 5-HT 3 receptor antagonists increased this percentage to approximately 70%. 17 Compared to other substance P/NK1 receptor antagonists, rolapitant may offer additional safety benefits because it has the lowest incidence of adverse effects. This better tolerance may, in turn, enhance overall patient compliance with the regimen. Another advantage of rolapitant is that it is not an inhibitor or an inducer of CYP3A4, thereby reducing the risk of clinically significant drug drug interactions. Because it is administered in one dose, rolapitant may offer the advantages of enhanced compliance and improved quality of life. Given the aforementioned benefits of rolapitant and its comparative pricing to other agents in the class, P&T committees should give rolapitant favorable consideration for formulary addition. CONCLUSION Rolapitant has demonstrated an excellent efficacy and safety profile in three phase 3 clinical trials. Additional comparative studies will be beneficial to determine the benefits of the drugs within the NK1 receptor antagonist class. A trial comparing rolapitant and the shorter-acting NK1 receptor antagonists will further help to solidify its place in therapy. REFERENCES 1. National Cancer Institute. Nausea and vomiting (PDQ) health professional version. January 4, Available at: www. cancer.gov/about-cancer/treatment/sideeffects/nausea/nausea-hp-pdq. Accessed July 10, National Comprehensive Cancer Network. Clinical practice guidelines for supportive care: antiemesis. Available at: Accessed July 10, Rice M. Management of chemotherapy induced nausea and vomiting. OncoLink- University of Pennsylvania. July Available at: management-of-chemotherapy-inducednausea-and-vomiting. Accessed July 10, Emend (aprepitant) capsules prescribing information. Whitehouse Station, New Jersey: Merck Sharp & Dohme Corp.; Varubi (rolapitant) prescribing information. Waltham, Massachusetts: Tesaro Inc.; Anzemet (dolasetron mesylate) tablets prescribing information. Bridgewater, New Jersey: Sanofi-Aventis; Kytril (granisetron hydrochloride) tablets prescribing information. Nutley, New Jersey: Roche Laboratories, Inc.; Zofran (ondansetron hydrochloride) tablets prescribing information. Research Triangle Park, North Carolina: Glaxo- SmithKline; Akynzeo (netupitant and palonosetron) capsules prescribing information. Woodcliff Lake, New Jersey: Eisai, Inc.; Red Book Online. Ann Arbor, Michigan; Truven Health Analytics. Accessed January 23, Aziz F. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting. Ann Palliat Med 2012;1(2): Sanger GJ. Neurokinin NK 1 and NK 3 receptors as targets for drugs to treat gastro intestinal motility disorders and pain. Br J Pharmacol 2004;141(8): Wang J, Wang X, Zhang ZY, et al. Pharmacokinetics of rolapitant in subjects with mild or moderate hepatic impairment [abstract T2335]. Presentation at AAPS Annual Meeting and Exposition, Orlando, Florida, October 25 29, Poma A, Christensen JC, Pentikis HP, et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Support Care Cancer 2013;21:S154;Abstr Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomized, active-controlled, double-blind phase 3 trial. Lancet Oncol 2015;16(9): Rapoport Bl, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatinbased highly emetogenic chemotherapy in patients with cancer: two randomized, active-controlled, double-blind phase 3 trials. Lancet Oncol 2015;16(9): Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 2015;26(6): Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016;374(14): n 172 P&T March 2017 Vol. 42 No. 3
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 6/15/18 Pharmacy- Formulary 1 x Next Review: 6/19 Pharmacy- Formulary 2 x Date of Origin: 4/99 Antiemetic Agents: Zofran /ODT (ondansetron/ondansetron
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More information9/21/2016. Disclosures. Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Introduction. Objectives.
Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Diwura Owolabi, Pharm.D, BCOP Clinical Pharmacy Specialist, Blood and Marrow Transplantation Methodist University Hospital,
More informationDennis J. Cada, PharmD, FASHP, FASCP (Editor) * ; Ross Bindler, PharmD ; and Danial E. Baker, PharmD, FASHP, FASCP
Hosp Pharm 2016;51(2):165 175 2016 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj5102-165 Formulary Drug Reviews Rolapitant Dennis J. Cada, PharmD, FASHP, FASCP (Editor) * ; Ross
More informationOverview of the neurokinin-1 receptor antagonists
Editorial Page 1 of 6 Overview of the neurokinin-1 receptor antagonists Rudolph M. avari Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, Birmingham, AL, USA Correspondence
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
More informationAvailable online at ScienceDirect. journal homepage:
European Journal of Cancer 57 (2016) 23e30 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.ejcancer.com Original Research Efficacy and safety of rolapitant for prevention
More informationClinical Policy: Oral Antiemetics (5-HT3 Antagonists) Reference Number: CP.PMN.11 Effective Date: Last Review Date: 05.18
Clinical Policy: (5-HT3 Antagonists) Reference Number: CP.PMN.11 Effective Date: 09.01.06 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
More informationDrug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting
Texas Vendor Drug Program Drug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting Publication History Developed September 1996. Revised July 2018; September 2016; June 2015;
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationRegulatory Status FDA-approved indications: Emend is a substance P/neurokinin 1 (NK1) receptor antagonist, indicated: (1-2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.05 Section: Prescription Drugs Effective Date: April 1, 2017 Subject: Emend Page: 1 of 6 Last Review
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More informationReviews on Recent Clinical Trials
Reviews on Recent Clinical Trials Send Orders for Reprints to reprints@benthamscience.ae 193 Reviews on Recent Clinical Trials, 2017, 12, 193-201 REVIEW ARTICLE ISSN: 1574-8871 eissn: 1876-1038 : An NK-1
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationComparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting
Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationVARUBI (rolapitant) tablets, for oral use VARUBI (rolapitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2015
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VARUBI safely and effectively. See full prescribing information for VARUBI. VARUBI (rolapitant) tablets,
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEMEND PRODUCT MONOGRAPH. aprepitant capsules. 80 and 125 mg. Neurokinin 1 (NK 1 ) receptor antagonist
PRODUCT MONOGRAPH EMEND aprepitant capsules 80 and 125 mg Neurokinin 1 (NK 1 ) receptor antagonist Merck Canada Inc. 16750 route Transcanadienne Kirkland, QC H9H 4M7 Canada Date of Revision: January 22,
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationClass Update with New Drug Evaluation: Antiemetics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPlease note: ASD Healthcare will continue to support and provide distribution for Varubi Oral tablets.
Customer Service P 800.746.6273 F 800.547.9413 M-Th 7:00a.m.-6:30p.m. (CST) F 7:00a.m.-6:00p.m. (CST) www.asdhealthcare.com Varubi IV Distribution Suspension March 14, 2018 Tesaro elects to suspend distribution
More informationEuropean Medicines Agency
European Medicines Agency SCIENTIFIC DISCUSSION 1. Introduction Emend is an oral substance P, aka human neurokinin 1 (NK-1)-receptor antagonist. Mammalian tachykinin substance P (SP) that binds to the
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, onceper-cycle treatment for the prevention
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationGeneric (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 9/11/2018 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 12/16, 11/15, 11/07 LOB AFFECTED
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationCME. The faculty reported the following financial relationships or relationships to
CME Target Audience This activity has been designed to meet the educational needs of oncologists, hematologists, and oncology nurses involved in the management of cancer patients receiving chemotherapy.
More informationClinical Policy: Netupitant and Palonosetron (Akynzeo) Reference Number: HIM.PA.113 Effective Date: Last Review Date: 05.
Clinical Policy: (Akynzeo) Reference Number: HIM.PA.113 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationDennis J. Cada, PharmD, FASHP, FASCP (Editor) * ; James Leonard ; and Danial E. Baker, PharmD, FASHP, FASCP
Hosp Pharm 2015;50(4):310 325 2015 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj5004-310 Formulary Drug Reviews Netupitant/ Dennis J. Cada, PharmD, FASHP, FASCP (Editor) * ; James
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationCADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report
CADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma) Indication: In combination with dexamethasone, once-percycle treatment for the prevention
More informationSue Faulkner, BSN RN OCN October 18, 2017 Updates from Congress 2017
Report: Occurrence and Implications of Chemotherapy-Induced nausea and Vomiting (CINV): Implications for the Oncology Nurse Practitioner to Optimize Patient Outcomes Sue Faulkner, BSN RN OCN October 18,
More informationDrug Class Literature Scan: Newer Antiemetics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSerotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs (5.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AKYNZEO safely and effectively. See full prescribing information for AKYNZEO. AKYNZEO (netupitant
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
1371 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(8): 1371-1377. doi: 10.7150/jca.17102 Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationCoding and Billing Guide for VARUBI Injectable Emulsion-IV and Tablets-Oral
Coding and Billing Guide for VARUBI Injectable Emulsion-IV and Tablets-Oral Please click here for full Prescribing Information and see Indication and Important Safety Information for VARUBI on page 3.
More informationChemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care
Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,
More informationDavid G. Frame, PharmD. he etiology of nausea and vomiting is multifactorial,
r e v i e w Best Practice Management of CINV in Oncology Patients: I. Physiology and Treatment of CINV Multiple Neurotransmitters and Receptors and the Need for Combination Therapeutic Approaches David
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationStudent Project PRACTICE-BASED RESEARCH
Pharmacist-Driven Management of Chemotherapy Induced Nausea and Vomiting in Hospitalized Adult Oncology Patients. A Retrospective Comparative Study Ramy Elshaboury, PharmD 1 and Kathleen Green, PharmD,
More informationONDANSETRON HCl AMNOSET 4 AMNOSET 6
For the use of a Registered Medical Practitioner, Hospital or a Laboratory only. Product Monograph ONDANSETRON HCl AMNOSET 4 AMNOSET 6 4mg Film-Coated Tablet 8mg Film-Coated Tablet Antiemetic Manufactured
More informationDECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***
Decontamination and Antiemetics Med 5724 Page 1 of 8 DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** REFERENCES: Katzung (9th ed.)
More informationChemotherapy-induced nausea and vomiting (CINV)
At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,
More informationCompany Update. September 2016
Company Update September 2016 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationComparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
569 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(5): 569-575. doi: 10.7150/jca.13637 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk
More informationSerotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs (5.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AKYNZEO safely and effectively. See full prescribing information for AKYNZEO. AKYNZEO (netupitant
More informationANTIEMETICS and FEBRILE NEUTROPENIA. Matti S. Aapro Genolier Switzerland
ANTIEMETICS and FEBRILE NEUTROPENIA Matti S. Aapro Genolier Switzerland 2010 Multinational Association of Supportive Care in Cancer TM All rights reserved worldwide. Disclosures Collaborations in this
More informationSupportive Care Select Topics Updated May 2017 by Dr. Charles Lim (PGY-5 Medical Oncology Resident, University of Toronto)
Supportive Care Select Topics Updated May 2017 by Dr. Charles Lim (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Warr (Staff Medical Oncologist, University of Toronto) DISCLAIMER:
More information